Americas Cancer Biologic Therapy Market Summary
The United States Americas Cancer Biological Therapy market is projected to grow from 98.4 USD Billion in 2024 to 133.4 USD Billion by 2035.
Key Market Trends & Highlights
Americas Cancer Biological Therapy Key Trends and Highlights
- The market is expected to experience a compound annual growth rate (CAGR) of 2.8 percent from 2025 to 2035.
- By 2035, the market valuation is anticipated to reach 133.4 USD Billion, indicating robust growth potential.
- In 2024, the market is valued at 98.4 USD Billion, reflecting a strong foundation for future expansion.
- Growing adoption of biological therapies due to increasing cancer prevalence is a major market driver.
Market Size & Forecast
2024 Market Size | 98.4 (USD Billion) |
2035 Market Size | 133.4 (USD Billion) |
CAGR (2025-2035) | 2.8% |
Major Players
Hoffmann-La Roche AG, GSK, Merck & Co., Novartis International AG, Inc., GlaxoSmithKline Plc, Bristol-Myers Squibb, Eli Lilly, Amgen Inc., Spectrum Pharmaceuticals, Inc., Seattle Genetics, Inc., Celgene Corporation